Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Biotechnology Stocks Technical Review -- MannKind, Array BioPharma, Arena Pharma, and Chimerix

NEW YORK, NY / ACCESSWIRE / February 8, 2016 / Park Lane Advisor has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), Array BioPharma Inc. (NASDAQ: ARRY), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Chimerix Inc. (NASDAQ: CMRX). Free note on MannKind can be accessed at http://www.parklaneadvisor.com/ On Friday, February 05, 2016, the NASDAQ Composite ended at 4,363.14, down 3.25%, the Dow Jones Industrial Average lost 1.29%, to finish the day at 16,204.97, and the S&P 500 closed at 1,880.05, down 1.85%. Register for your complimentary reports at the links given below.

MannKind Corp.'s stock declined 1.34%, to close the day at $0.97. The stock recorded a trading volume of 2.82 million shares, much below its three months average volume of 8.20 million shares. MannKind Corp.'s shares have surged 32.81% in the last one month, but the stock has plummeted 67.63% in the previous three months. The company's shares are trading 27.70% below their 50-day moving average. Additionally, MannKind Corp. has a Relative Strength Index (RSI) of 45.82. Sign up and read the free notes on MNKD at:

http://www.parklaneadvisor.com/

On Friday, shares in Array BioPharma Inc. recorded a trading volume of 2.60 million shares, lower than their three months average volume of 3.15 million shares. The stock ended the day 3.64% lower at $2.91. Shares of the company traded at a PE ratio of 58.20. The company is trading below its 50-day and 200-day moving averages by 22.44% and 47.53%, respectively. Furthermore, shares of Array BioPharma Inc. have an RSI of 33.26. The complimentary notes on ARRY can be downloaded in PDF format at:

http://www.parklaneadvisor.com/

Arena Pharmaceuticals Inc.'s stock finished Friday's session 2.48% lower at $1.57. A total of 2.31 million shares were traded, which was below its three months average volume of 2.89 million shares. The company’s shares are trading below their 50-day and 200-day moving averages by 13.74% and 47.21%, respectively. Arena Pharmaceuticals Inc.'s stock has an RSI of 46.17. Register for free on Park Lane Advisor and access the latest research on ARNA at:

http://www.parklaneadvisor.com/

On Friday, shares in Chimerix Inc. ended the session 5.07% lower at $6.93. The stock reported a trading volume of 1.93 million shares, below its three months average volume of 2.83 million shares. The company is trading 67.56% below its 50-day moving average and 81.87% below its 200-day moving average. Moreover, shares of Chimerix Inc. have an RSI of 23.09. The complete research on CMRX is available for free at:

http://www.parklaneadvisor.com/

About Park Lane Advisor:

Park Lane Advisor ("PLA") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. PLA has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PLA has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY:

PLA, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING:

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PLA nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit www.ParkLaneAdvisor.com.

RESTRICTIONS:

PLA is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CONTACT:

For any questions, inquiries, or comments reach out to us directly at:

E-mail: media (at) ParkLaneAdvisor (dot) com

SOURCE: Park Lane Advisor

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.